Is the PFS benefit sufficient to adopt up front acalabrutinib plus BR for all patients with MCL?

In my opinion, PFS is not sufficient to adopt BR-acala as a universal treatment, but this can be an important treatment option for many patients. I would offer the BR-acala combo in patients who value maximizing duration of treatment response, recognizing this is a continuous regimen. On the other hand, I would prefer BR and saving BTKi in the second line if there is major concern about toxicities, cost, or strong preference for fixed duration therapy. This may be preferred for older patients or those with specific co-morbidities, for example.

As above, the magnitude of benefit is significant, but not "massive" (HR 0.73, 27% reduction in disease progression or death); and long-term BTK can mean a very long duration of immunosuppressive therapy without a break for these patients. I therefore prefer to target this approach to higher-risk patients.

The short answer is no. The ECHO data supports acalabrutinib plus BR as a reasonable, now guideline-preferred option for the specific population studied, but they do not justify blanket adoption for all patients with MCL. The benefit was a real but moderate PFS gain confined to older, transplant-ineligible patients, without an overall survival advantage, and at a cost of continuous therapy and non-trivial toxicity. So, it is not positioned as a universal standard. TP53-mutated MCL responds poorly to BTKi + chemoimmunotherapy and is handled separately. ECHO reported benefit "across subgroups including high-risk," but the trial was not powered to establish adequacy of this regimen in TP53-mutated MCL (Wang et al., PMID 40311141).

Furthermore, ...